Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
November 2017
-
Media ReleaseNovartis and Amgen announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention programParties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD) Clinical trial is part of the…
-
Media ReleaseNovartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell diseasePrimary results of pivotal KymriahTM Phase II JULIET study in relapsed/refractory DLBCL Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to…
-
Exploring longstanding questions about heart disease
New Global Head of Cardiovascular and Metabolic Diseases Research looks to apply new tools to address tough challenges
October 2017
-
Media ReleaseNovartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapySubmission based on updated analyses from global, multi-center Phase II JULIET study, which met primary endpoint, including 6-month data to be presented at ASH 2017 Kymriah has demonstrated…
-
Media ReleaseNovartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsALong-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting[1],[2] Structural disease progression is a…
-
Media ReleaseNovartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolioNovartis to acquire Advanced Accelerator Applications pending outcome of tender offer and works council consultation Acquisition would add Lutathera®, a first-in-class RadioLigand Therapy (…
-
Media ReleaseNovartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1aPARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on interferon beta-1a Currently there are no specifically approved disease…
-
Media ReleaseSandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory reviewComprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality Pegfilgrastim is a long-acting version of…
-
Media ReleaseNovartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMSFull data from the pivotal Phase III PARADIGMS study of Gilenya® (fingolimod) in pediatric MS will be presented for the first time With 54 accepted abstracts, Novartis presence spans from…
-
Media ReleaseNovartis delivered growth on top and bottom line in all divisions in Q3Net sales grew 2% (cc[1], +2% USD), with growth in all divisions: Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications Entresto (USD 128 million, +138% cc) grew…
-
Media ReleaseNovartis: au troisième trimestre, croissance du chiffre d'affaires et du résultat dans toutes les divisionsChiffre d'affaires net en hausse de 2% (tcc[1], +2% USD), avec une croissance dans toutes les divisions: Cosentyx (USD 556 millions, +83% tcc) a affiché une forte hausse dans toutes ses…
-
Media ReleaseNovartis steigert im dritten Quartal Umsatz und Gewinn in allen DivisionenDer Nettoumsatz steigt mit einem Wachstum in allen Divisionen um 2% (kWk[1], +2% USD): Cosentyx (USD 556 Millionen, +83% kWk) wächst in allen Indikationen stark Entresto (USD 128 Millionen, +…
Pagination
- ‹ Previous page
- 1
- …
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- …
- 152
- › Next page